Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;76(3):318-325.
doi: 10.1001/jamaneurol.2018.3746.

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders

Bob Olsson  1   2 , Erik Portelius  1   2 , Nicholas C Cullen  1   3 , Åsa Sandelius  1 , Henrik Zetterberg  1   2   4   5 , Ulf Andreasson  1   2 , Kina Höglund  1   2 , David J Irwin  6 , Murray Grossman  6 , Daniel Weintraub  3   7   8 , Alice Chen-Plotkin  6 , David Wolk  6 , Leo McCluskey  6 , Lauren Elman  6 , Leslie M Shaw  9 , Jon B Toledo  9   10 , Jennifer McBride  9 , Pilar Hernandez-Con  6 , Virginia M-Y Lee  9 , John Q Trojanowski  9 , Kaj Blennow  1   2
Affiliations

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders

Bob Olsson et al. JAMA Neurol. .

Abstract

Importance: Neuronal and axonal destruction are hallmarks of neurodegenerative diseases, but it is difficult to estimate the extent and progress of the damage in the disease process.

Objective: To investigate cerebrospinal fluid (CSF) levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders (determined by clinical criteria and autopsy), and determine its association with longitudinal cognitive decline.

Design, setting, and participants: In this case-control study, we investigated NFL levels in CSF obtained from controls and patients with several neurodegenerative diseases. Collection of samples occurred between 1996 and 2014, patients were followed up longitudinally for cognitive testing, and a portion were autopsied in a single center (University of Pennsylvania). Data were analyzed throughout 2016.

Exposures: Concentrations of NFL in CSF.

Main outcomes and measures: Levels of CSF NFL and correlations with cognition scores.

Results: A total of 913 participants (mean [SD] age, 68.7 [10.0] years; 456 [49.9%] women) were included: 75 control participants plus 114 patients with mild cognitive impairment (MCI), 397 with Alzheimer disease, 96 with frontotemporal dementia, 68 with amyotrophic lateral sclerosis, 41 with Parkinson disease (PD), 19 with PD with MCI, 29 with PD dementia, 33 with dementia with Lewy bodies, 21 with corticobasal syndrome, and 20 with progressive supranuclear palsy. Cognitive testing follow-up occurred for 1 to 18 years (mean [SD], 0.98 [2.25] years); autopsy-verified diagnoses were available for 120 of 845 participants with diseases (14.2%). There was a stepwise increase in CSF NFL levels between control participants (median [range] score, 536 [398-777] pg/mL), participants with MCI (831 [526-1075] pg/mL), and those with Alzheimer disease (951 [758-1261] pg/mL), indicating that NFL levels increase with increasing cognitive impairment. Levels of NFL correlated inversely with baseline Mini-Mental State Examination scores (ρ, -0.19; P < .001) in the full cohort (n = 822) and annual score decline in the full cohort (ρ, 0.36, P < .001), participants with AD (ρ, 0.25; P < .001), and participants with FTD (ρ, 0.46; P = .003). Concentrations of NFL were highest in participants with amyotrophic lateral sclerosis (median [range], 4185 [2207-7453] pg/mL) and frontotemporal dementia (2094 [230-7744] pg/mL). In individuals with parkinsonian disorders, NFL concentrations were highest in those with progressive supranuclear palsy (median [range], 1578 [1287-3104] pg/mL) and corticobasal degeneration (1281 [828-2713] pg/mL). The NFL concentrations in CSF correlated with TDP-43 load in 13 of 17 brain regions in the full cohort. Adding NFL to β-amyloid 42, total tau, and phosphorylated tau increased accuracy of discrimination of diseases.

Conclusions and relevance: Levels of CSF NFL are associated with cognitive impairments in patients with Alzheimer disease and frontotemporal dementia. In other neurodegenerative disorders, NFL levels appear to reflect the intensity of the neurodegenerative processes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wolk received grant funding from Merck, Biogen, Avid Radiopharmaceuticals. and Eli Lilly and personal fees from GE Healthcare, Merck, and Janssen. Dr Zetterberg is a cofounder of Brain Biomarker Solutions in Gothenburg AB (a GU Venture–based platform company at the University of Gothenburg), has served on advisory boards of Eli Lilly and Roche Diagnostics, and has received travel support from TEVA. Dr Blennow has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (a GU Venture–based platform company at the University of Gothenburg). No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Neurofilament Light Protein in Control Participants and Participants With Mild Cognitive Impairment, Dementias, and Amyotrophic Lateral Sclerosis
A, Cerebrospinal fluid levels of neurofilament light in control participants, participants with mild cognitive impairment, and participants with Alzheimer disease. The graph omits outlier data points (neurofilament light levels >5000 pg/mL) for 1 control participant, 1 with mild cognitive impairment, and 3 with Alzheimer disease. B, The levels of neurofilament light in cerebrospinal fluid in control participants, participants with forms of dementia, and participants with amyotrophic lateral sclerosis. The graph omits outlier data points (neurofilament light levels >10 000 pg/mL) for 1 participant with dementia with Lewy bodies, 1 with Alzheimer disease, and 7 with amyotrophic lateral sclerosis.
Figure 2.
Figure 2.. Neurofilament Light (NFL) Protein in Control Participants and Participants With Movement Disorders
The graph omits outlier data points (neurofilament light levels >5000 pg/mL) for 1 participant with progressive supranuclear palsy, 2 with corticobasal degeneration, 1 with dementia with Lewy bodies, 1 with Parkinson disease, 1 with Parkinson disease with mild cognitive impairment, and 1 control participant.
Figure 3.
Figure 3.. Neurofilament Light Protein in Participants With Autopsy-Verified Neurodegenerative Diseases
Neurofilament light levels in clinically diagnosed control participants are added as a dotted line for reference. The graph omits outlier data points (neurofilament light levels >5000 pg/mL) for 1 participant with frontotemporal lobe degeneration and 2 with amyotrophic lateral sclerosis.
Figure 4.
Figure 4.. Correlations Between Neurofilament Light Protein and Annual Mini-Mental State Examination Score Decline
Correlations between cerebrospinal fluid levels of neurofilament light and the magnitude of annual decline in Mini-Mental State Examination scores in participants with Alzheimer disease (ρ = 0.25; P < .001) (A), frontotemporal dementia (ρ = 0.46; P = .003) (B), and all participants (ρ = 0.36; P < .001) (C).
See this image and copyright information in PMC

References

    1. Westermann D, Neumann JT, Sörensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017;14(8):472-483. doi:10.1038/nrcardio.2017.48 - DOI - PubMed
    1. Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3 - DOI - PubMed
    1. Yamasaki H, Itakura C, Mizutani M. Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathol. 1991;82(6):427-434. doi:10.1007/BF00293376 - DOI - PubMed
    1. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013-2018. doi:10.1046/j.1471-4159.1996.67052013.x - DOI - PubMed
    1. Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999;52(5):1090-1093. doi:10.1212/WNL.52.5.1090 - DOI - PubMed

Publication types

MeSH terms